IsoPlexis to Report Second Quarter 2022 Financial Results on August 10, 2022

BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.

About IsoPlexis

IsoPlexis is the Superhuman Cell company.

By leading the discovery and identification of how multi-functional immune— Superhuman— cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and at over 70% of leading U.S. comprehensive cancer centers.

Investor Contact
investors@isoplexis.com

Press Contact
press@isoplexis.com

Staff

Recent Posts

American College of Osteopathic Family Physicians Announces 2024-2025 Board of Governors

CHICAGO, IL / ACCESSWIRE / April 3, 2024 / The American College of Osteopathic Family…

3 hours ago

ACOFP Foundation Announces New Campaign, Family Medicine Forward

Campaign underscores the urgency and need to support early career osteopathic family physicians.CHICAGO, IL /…

6 hours ago

Reveal Lasers Reports First Quarter With Record-Breaking 300% Growth

LAS VEGAS, NV / ACCESSWIRE / April 3, 2024 / Reveal Lasers, a burgeoning force…

9 hours ago

Weave Enhances Integration with DrChrono by EverHealth

Deeper integration unlocks powerful Weave features to improve patient experiencesLEHI, Utah--(BUSINESS WIRE)--Weave (NYSE: WEAV), a…

12 hours ago

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that…

12 hours ago

LPW Training Services Awarded the Association for Talent Development’s Excellence in Practice for 2024

SOMERVILLE, NJ / ACCESSWIRE / April 3, 2024 / LPW Training Services, a global industry…

12 hours ago